Study
DHA Supplementation Shows No Added Benefit During Breast Cancer Treatment
Taking DHA supplements during breast cancer therapy did not significantly enhance treatment effectiveness, but was safe and well-tolerated.
Summary
In plain language
A recent study looked into whether taking docosahexaenoic acid (DHA), an omega-3 fatty acid, during breast cancer treatment could improve outcomes. Researchers found that while DHA was safe and doubled in the blood of those who took it, it did not significantly enhance the effectiveness of the cancer treatment compared to a placebo. This means that while DHA is safe to take, it doesn't seem to offer additional benefits in terms of reducing cancer cell activity during neoadjuvant chemotherapy. Seniors undergoing treatment for breast cancer might discuss with their doctors whether DHA supplements are suitable for them, considering these findings.
Details
Use the full description to understand the study design, methods, and the limits of the findings.
This study involved 49 women with breast cancer who were given either DHA supplements or a placebo during chemotherapy.
Researchers observed no significant difference in cancer cell activity reduction, measured by Ki-67 expression, between those taking DHA and those on placebo.
DHA levels in the blood increased for those taking the supplement, indicating good absorption without adverse effects.
While DHA didn’t improve treatment outcomes, it was safe and might still hold other health benefits.
Seniors should talk to their healthcare providers about the role of DHA in their treatment plans, considering individual health needs.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
DHA Supplementation Shows No Added Benefit During Breast Cancer Treatment
Published October 2026
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored October 22, 2026 using rubric mq-1.8_2026-07-06.
Assessment
The study scored highly in design and bias control due to its RCT structure with blinding and allocation concealment. Statistical integrity was strong with pre-specified endpoints and adequate power. Transparency was complete with pre-registration. However, conflicts of interest were not disclosed, and no replication evidence was provided. Relevance was partial due to unspecified age distribution, and journal quality could not be assessed.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 10.0/10 | |
| Bias control | 10.0/10 | |
| Statistical methods | 10.0/10 | |
| Reporting completeness | 10.0/10 | |
| Conflicts & funding | 0.0/10 | |
| Replication | 0.0/10 | |
| Relevance to chosen population | 5.0/10 | |
| Journal Reliability | 5.0/10 |
Additional Notes
The DHA-WIN trial investigated the safety and efficacy of DHA supplementation during neoadjuvant chemotherapy for breast cancer. It found no significant benefit of DHA on Ki-67 expression or pathological complete response rates, though DHA was well tolerated.
Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were reviewed.
Conditions This Research Covers
These condition pages help connect the paper back to the real-world health concerns it addresses.
Treatments Evaluated in This Research
Review the interventions studied here and compare them against the broader treatment library.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.